Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Geron
GERN
Geron
Drug Pricing Controls And Approval Delays Will Curb Viability
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
22 Aug 25
Updated
22 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$1.00
46.0% overvalued
intrinsic discount
22 Aug
US$1.46
Loading
1Y
-67.8%
7D
0.7%
Author's Valuation
US$1.0
46.0% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$1.0
46.0% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-201m
430m
2014
2017
2020
2023
2025
2026
2028
Revenue US$429.6m
Earnings US$69.8m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
36.96%
Biotech revenue growth rate
11.97%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.85%
Calculation
US$69.81m
Earnings '28
x
13.10x
PE Ratio '28
=
US$914.51m
Market Cap '28
US$914.51m
Market Cap '28
/
750.13m
No. shares '28
=
US$1.22
Share Price '28
US$1.22
Share Price '28
Discounted to 2025 @ 6.83% p.a.
=
US$1.00
Fair Value '25
